Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Status:
RECRUITING
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
As part of postremission consolidative therapy, the decision to proceed with hematopoietic stem cell transplantation is a recommendable regimen in ALL therapy. However, The recurrence rate is high after transplantation. Minimal Residual Disease (MRD) is an important factor affecting the effect of HSCT. The hematologic recurrence rate of MRD-positive patients with adult ALL is high.
MRD- is associated with better prognosis. Therefore, maintaining MRD- after transplantation is necessary for long-term survival. The purpose of this study is to explore the efficacy and safety of Inotuzumab Ozogamicin in the treatment of minimal residual disease recurrence after HSCT of ALL patients.
Phase:
PHASE2
Details
Lead Sponsor:
Sheng-Li Xue, MD
Collaborators:
Affiliated Hospital of Nantong University Jining Medical University Northern Jiangsu People's Hospital Suzhou Hospital of Traditional Chinese Medicine The First Affiliated Hospital of Bengbu Medical University The Second People's Hospital of Huai'an